Laurion Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Laurion Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,886	Closed	-$977K	–	1161
2019 Q1	$977K	Buy	+27,886	New	+$1.04M	0.01%	509
2018 Q4	–	Sell	-4,094	Closed	-$207K	–	1394
2018 Q3	$207K	Buy	+4,094	New	+$202K	﹤0.01%	1041
2018 Q2	–	Sell	-5,997	Closed	-$275K	–	1572
2018 Q1	$275K	Buy	+5,997	New	+$250K	﹤0.01%	1153
2016 Q2	–	Sell	-17,300	Closed	-$264K	–	1008
2016 Q1	$264K	Sell	17,300 -600	-3%	-$7.83K	﹤0.01%	624
2015 Q4	$241K	Buy	+17,900	New	+$277K	﹤0.01%	780

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Laurion Capital Management's SUPN Position: Q2 2019 in Review

Laurion Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 27,886 shares — an estimated $977K sold.

Laurion Capital Management first reported a position in SUPN in Q4 2015 and held it in 5 quarters. The position peaked at $977K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Laurion Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Laurion Capital Management sold 27,886 Supernus Pharmaceuticals shares in Q2 2019, an estimated $977K.
Laurion Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 5 quarters.
Laurion Capital Management's Supernus Pharmaceuticals position peaked at $977K in Q1 2019.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.